Inventor · disambiguated record
Jonathan Mark Sutton
Also filed as: SUTTON JONATHAN M · SUTTON JONATHAN MARK
34 granted patents·10 pending applications·107 citations·filing 2001–2024
96Inventor score
Top patents by PatentIndex Score
44 records- 0193US11820751B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2022·Granted Nov 21, 2023·3 cites·6 claims
- 0292US11680068B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Granted Jun 20, 2023·1 cites·14 claims
- 0391US7326732B2EP2 receptor agonistsPHARMAGENE LAB LTD·Filed 2005·Granted Feb 5, 2008·18 cites·8 claims
- 0490US11352361B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2018·Granted Jun 7, 2022·3 cites·22 claims
- 0589US10954241B2Heterocyclic compounds as ret kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Mar 23, 2021·3 cites·29 claims
- 0689US7803841B2EP2 receptor agonistsASTERAND UK LTD·Filed 2008·Granted Sep 28, 2010·11 cites·13 claims
- 0788US10844067B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Nov 24, 2020·4 cites·27 claims
- 0887US11548896B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2021·Granted Jan 10, 2023·1 cites·30 claims
- 0987US10023558B2CompoundsCHIESI FARM SPA·Filed 2017·Granted Jul 17, 2018·6 cites·20 claims
- 1086US9802919B1CompoundsCHIESI FARM SPA·Filed 2017·Granted Oct 31, 2017·5 cites·14 claims
- 1186US7662839B2EP2 receptor agonistsASTERAND UK LTD·Filed 2007·Granted Feb 16, 2010·7 cites·15 claims
- 1285US11661423B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2020·Granted May 30, 2023·1 cites·24 claims
- 1385US2025236624A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 1484US12473269B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Nov 18, 2025·0 cites·12 claims
- 1584US9409870B2CompoundsCHIESI FARM SPA·Filed 2015·Granted Aug 9, 2016·5 cites·12 claims
- 1684US7528157B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2006·Granted May 5, 2009·3 cites·24 claims
- 1784US7507754B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2007·Granted Mar 24, 2009·3 cites·41 claims
- 1883US12358884B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 1982US12351567B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 8, 2025·0 cites·19 claims
- 2082US9023855B2CompoundsCHIESI FARMA SPA·Filed 2014·Granted May 5, 2015·2 cites·20 claims
- 2182US2025243202A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 2281US7196089B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Mar 27, 2007·8 cites·30 claims
- 2381US2024132504A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 2479US8691826B2CompoundsBLENCH TOBY JONATHAN·Filed 2012·Granted Apr 8, 2014·5 cites·17 claims
- 2578US2023339954A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Application pending·0 cites
- 2677US7417068B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Aug 26, 2008·8 cites·15 claims
- 2776US11000511B2Chemical compounds as antibioticsANTABIO SAS·Filed 2018·Granted May 11, 2021·2 cites·38 claims
- 2876US2024116938A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 2975US7569602B2Furan derivatives as EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Aug 4, 2009·6 cites·13 claims
- 3073US8080567B2EP2 receptor agonistsOXFORD ALEXANDER WILLIAM·Filed 2006·Granted Dec 20, 2011·2 cites·21 claims
- 3168US7858644B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2009·Granted Dec 28, 2010·0 cites·23 claims
- 3261US2008306117A1Ep4 receptor antagonistsASTERAND UK LTD·Filed 2008·Application pending·0 cites
- 3354US9365577B2Pyrimidinone compounds as human neutrophil elastase inhibitorsCHIESI FARMA SPA·Filed 2013·Granted Jun 14, 2016·0 cites·16 claims
- 3452US2010261760A1EP2 Receptor AgonistsASTERAND UK LTD·Filed 2010·Application pending·0 cites
- 3547US9573955B2CompoundsCHIESI FARM SPA·Filed 2014·Granted Feb 21, 2017·0 cites·14 claims
- 3646US9868740B2Pyrimidinone compounds which are HNE inhibitorsCHIESI FARM SPA·Filed 2014·Granted Jan 16, 2018·0 cites·13 claims
- 3746US9828382B2Pyrimidinone compounds as human neutrophil elastase inhibitorsCHIESI FARM SPA·Filed 2016·Granted Nov 28, 2017·0 cites·17 claims
- 3846US9199984B2Inhibition of enzymesCHIESI FARMA SPA·Filed 2013·Granted Dec 1, 2015·0 cites·17 claims
- 3943US2006063792A1Substituted morphinans and methods of their useADOLOR CORP·Filed 2005·Application pending·0 cites
- 4041US10172830B2Pyrazolone compounds having human neutrophil elastase inhibitory propertiesCHIESI FARM SPA·Filed 2017·Granted Jan 8, 2019·0 cites·15 claims
- 4136US9487528B2CompoundsCHIESI FARM SPA·Filed 2015·Granted Nov 8, 2016·0 cites·27 claims
- 4235US11649237B2Substituted imidazo[1,5-a]pyrazines for IRE1 inhibitionOPTIKIRA LLC·Filed 2018·Granted May 16, 2023·0 cites·18 claims
- 4335US2009192138A1compoundsBAESCHLIN DANIEL KASPAR·Filed 2006·Application pending·0 cites
- 4426US2003203888A1ChromophoresFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →